Table 2.
Systemic lupus erythematosus drug treatments.
| Drug treatments | Patients, n (%) | |||
| Health insurance claims data (EphMRA ATCa classification of drug [code]) |
|
|||
|
|
All patients | 4694 (100) | ||
|
|
|
Oral corticosteroids, plain [H02A2] | 2529 (53.9) | |
|
|
|
Proton pump inhibitors [A02B2] | 1622 (34.6) | |
|
|
|
Antirheumatics, nonsteroidal plain [M01A1] | 1432 (30.5) | |
|
|
|
All other antiulcerants [A02B9] | 1333 (28.4) | |
|
|
|
Other immunosuppressants [L04X-] | 1266 (27.0) | |
|
|
|
Bisphosphonates for osteoporosis and related disorders [M05B3] | 1224 (26.1) | |
|
|
|
Vitamin D [A11C2] | 1129 (24.1) | |
|
|
|
Nonnarcotics and antipyretics [N02B-] | 1089 (23.2) | |
|
|
|
Topical antirheumatics and analgesics [M02A-] | 1083 (23.1) | |
|
|
|
Systemic antihistamines [R06A-] | 1023 (21.8) | |
|
|
|
Plain topical corticosteroids [D07A-] | 891 (19.0) | |
|
|
|
Statins (HMG-CoA reductase inhibitors) [C10A1] | 771 (16.4) | |
|
|
|
H2 antagonists [A02B1] | 745 (15.9) | |
|
|
|
Expectorants [R05C-] | 738 (15.7) | |
|
|
|
Angiotensin-II antagonists, plain [C09C-] | 731 (15.6) | |
| Tōbyōki blog data (generic name of drug) |
|
|||
|
|
All patients | 671 (100) | ||
|
|
|
Steroid | 499 (74.4) | |
|
|
|
Prednisolone | 470 (70.0) | |
|
|
|
Loxoprofen sodium hydrate | 220 (32.8) | |
|
|
|
Tacrolimus hydrate | 190 (28.3) | |
|
|
|
Alendronate sodium hydrate | 114 (17.0) | |
|
|
|
Aspirin | 109 (16.2) | |
|
|
|
Acetaminophen | 104 (15.5) | |
|
|
|
Lidocaine, Adrenaline bitartrate | 101 (15.1) | |
|
|
|
Cyclophosphamide hydrate | 99 (14.8) | |
|
|
|
Azathioprine | 93 (13.9) | |
|
|
|
Alfacalcidol | 89 (13.3) | |
|
|
|
Aztreonam | 88 (13.1) | |
|
|
|
Calcium L-aspartate hydrate | 83 (12.4) | |
|
|
|
Cyclophosphamide hydrate | 82 (12.2) | |
|
|
|
Mycophenolate mofetil | 80 (11.9) | |
aAnatomical Therapeutic Chemical classification.